{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:12:57Z","timestamp":1766067177275,"version":"3.48.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treatment in phenylketonuria is based on using a diet aimed at protecting the brain from uncontrolled hyperphenylalaninemia. Although treatment methods are well established, clinical outcomes vary among patients. This may be due to alterations of phenylalanine transport mediated by the amino acid transporter LAT1, which also regulates the function of the mTORC1\/proteasomal pathway. We investigated the clinical and cellular effects of a structural variant in the\n                    <jats:italic>SLC7A5<\/jats:italic>\n                    gene, which encodes LAT1. The investigated variant was previously associated with altered phenylalanine metabolism in preliminary studies. We assessed physical and intellectual development in children with phenylketonuria. Next, we explored the cellular mechanisms underlying potential phenotypic differences between carriers and noncarriers of the rs113883650 polymorphism \u2013 a marker of the studied\n                    <jats:italic>SLC7A5<\/jats:italic>\n                    variant. For cellular experiments we used a model of hyperphenylalaninemia based on induced pluripotent stem cells. We assessed LAT1 abundance and performed transcriptomic and proteomic analyses. We found that carriers of rs113883650 were more prone to being overweight but exhibited significantly better intellectual development. They also showed a corresponding increased LAT1 abundance and decreased expression of proteasomal genes and the FOXO signalling pathway. We propose considering of the rs113883650 status during the follow-up of children with phenylketonuria. It may also hold relevance in other LAT1-related conditions including cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-31622-w","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T19:45:14Z","timestamp":1765568714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteasomal activity and disease outcome in phenylketonuria patients with a structural SLC7A5 variant"],"prefix":"10.1038","volume":"15","author":[{"given":"Miroslaw","family":"Bik-Multanowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Bobis-Wozowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Piejko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Madetko-Talowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Kopaczka-Koziol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomir","family":"Lasota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urszula","family":"Jankowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Skupien-Rabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Korycinska-Chaaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Krzywdzinska-Rogowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ortrud K.","family":"Steinlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"31622_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau, N., van Spronsen, F. J. & Levy, H. L. Phenylketonuria. Lancet 376, 1417\u20131427. https:\/\/doi.org\/10.1016\/S0140-6736(10)60961-0 (2010).","journal-title":"Lancet"},{"key":"31622_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg, A. M. J. et al. The complete European guidelines on phenylketonuria: Diagnosis and treatment. Orphanet J. Rare Dis. 12, 162. https:\/\/doi.org\/10.1186\/s13023-017-0685-2 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"31622_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ymgme.2022.07.012","volume":"137","author":"BK Burton","year":"2022","unstructured":"Burton, B. K. et al. Management of early treated adolescents and young adults with phenylketonuria: Development of international consensus recommendations using a modified Delphi approach. Mol. Genet. Metab. 137, 114\u2013126. https:\/\/doi.org\/10.1016\/j.ymgme.2022.07.012 (2022).","journal-title":"Mol. Genet. Metab."},{"key":"31622_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1086\/301920","volume":"63","author":"P Guldberg","year":"1998","unstructured":"Guldberg, P. et al. A European multicenter study of phenylalanine hydroxylase deficiency: Classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am. J. Hum. Genet. 63, 71\u201379. https:\/\/doi.org\/10.1086\/301920 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"31622_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.18388\/abp.2013_2029","volume":"60","author":"M Bik-Multanowski","year":"2013","unstructured":"Bik-Multanowski, M. et al. Molecular genetics of PKU in Poland and potential impact of mutations on BH4 responsiveness. Acta Biochim. Pol. 60, 613\u2013616 (2013).","journal-title":"Acta Biochim. Pol."},{"key":"31622_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","volume":"107","author":"A Hillert","year":"2020","unstructured":"Hillert, A. et al. The genetic landscape and epidemiology of phenylketonuria. Am. J. Hum. Genet. 107, 234\u2013250. https:\/\/doi.org\/10.1016\/j.ajhg.2020.06.006 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"31622_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/s0140-6736(02)09334-0","volume":"360","author":"JH Walter","year":"2002","unstructured":"Walter, J.H. et al. How practical are recommendations for dietary control in phenylketonuria? Lancet 360, 55\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(02)09334-0 (2002).","journal-title":"Lancet"},{"key":"31622_CR8","doi-asserted-by":"publisher","first-page":"S415","DOI":"10.1007\/s10545-008-0978-7","volume":"31","author":"M Bik-Multanowski","year":"2008","unstructured":"Bik-Multanowski, M. et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J. Inherit. Metab. Dis. 31, S415\u2013418. https:\/\/doi.org\/10.1007\/s10545-008-0978-7 (2008).","journal-title":"J. Inherit. Metab. Dis."},{"key":"31622_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/BF02276719","volume":"154","author":"BA Stemerdink","year":"1995","unstructured":"Stemerdink, B. A. et al. Information processing in patients with early and continuously treated phenylketonuria. Eur. J. Pediatr. 154, 739\u2013746. https:\/\/doi.org\/10.1007\/BF02276719 (1995).","journal-title":"Eur. J. Pediatr."},{"key":"31622_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.18388\/abp.2017_1524","volume":"64","author":"B Didycz","year":"2017","unstructured":"Didycz, B. & Bik-Multanowski, M. Dynamics of hyperphenylalaninemia and intellectual outcome in teenagers with phenylketonuria. Acta Biochim. Pol. 64, 527\u2013531. https:\/\/doi.org\/10.18388\/abp.2017_1524 (2017).","journal-title":"Acta Biochim. Pol."},{"key":"31622_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ymgmr.2017.12.003","volume":"14","author":"B Didycz","year":"2018","unstructured":"Didycz, B. & Bik-Multanowski, M. Blood phenylalanine instability strongly correlates with anxiety in phenylketonuria. Mol. Genet. Metab. Rep. 14, 80\u201382. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.003 (2018).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"31622_CR12","doi-asserted-by":"publisher","first-page":"107684","DOI":"10.1016\/j.ymgme.2023.107684","volume":"140","author":"A De Giorgi","year":"2023","unstructured":"De Giorgi, A., Nardecchia, F., Romani, C. & Leuzzi, V. Metabolic control and clinical outcome in adolescents with phenylketonuria. Mol. Genet. Metab. 140, 107684. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107684 (2023).","journal-title":"Mol. Genet. Metab."},{"key":"31622_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","volume":"7","author":"FJ van Spronsen","year":"2021","unstructured":"van Spronsen, F. J. et al. Phenylketonuria. Nat. Rev. Dis. Primers 7, 36. https:\/\/doi.org\/10.1038\/s41572-021-00267-0. (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"31622_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ymgme.2018.09.006","volume":"125","author":"BK Burton","year":"2018","unstructured":"Burton, B. K. et al. Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria. Mol. Genet. Metab. 125, 228\u2013234. https:\/\/doi.org\/10.1016\/j.ymgme.2018.09.006 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"31622_CR15","first-page":"143","volume":"116","author":"DY Hsia","year":"1998","unstructured":"Hsia, D. Y., O\u2019Flynn, M. E. & Berman, J. L. Atypical phenylketonuria with borderline or normal intelligence. Am. J. Dis. Child. 116, 143\u2013157 (1998).","journal-title":"Am. J. Dis. Child."},{"key":"31622_CR16","first-page":"239","volume":"27","author":"DA Primrose","year":"1983","unstructured":"Primrose, D. A. Phenylketonuria with normal intelligence. J. Ment Defic. Res. 27, 239\u2013246 (1983).","journal-title":"J. Ment Defic. Res."},{"key":"31622_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1023\/B:BOLI.0000045758.86492.54","volume":"27","author":"WB Hanley","year":"2004","unstructured":"Hanley, W. B. et al. Maternal phenylketonuria collaborative study (MPKUCS)--the \u2018outliers\u2019. J. Inherit. Metab. Dis. 27, 711\u2013723 (2004).","journal-title":"J. Inherit. Metab. Dis."},{"key":"31622_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13023-018-0890-7","volume":"13","author":"D van Vliet","year":"2018","unstructured":"van Vliet, D. et al. Can untreated PKU patients escape from intellectual disability? A systematic review. Orphanet J. Rare Dis. 13, 149. https:\/\/doi.org\/10.1186\/s13023-018-0890-7 (2018).","journal-title":"Orphanet J. Rare Dis."},{"key":"31622_CR19","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.3390\/nu11112572","volume":"11","author":"D van Vliet","year":"2019","unstructured":"van Vliet, D. et al. Untreated PKU patients without intellectual disability: what do they teach us? Nutrients 11, 2572. https:\/\/doi.org\/10.3390\/nu11112572 (2019).","journal-title":"Nutrients"},{"key":"31622_CR20","doi-asserted-by":"publisher","first-page":"100822","DOI":"10.1016\/j.ymgmr.2021.100822","volume":"29","author":"K Klaassen","year":"2021","unstructured":"Klaassen, K. et al. Untreated PKU patients without intellectual disability: SHANK gene family as a candidate modifier. Mol. Genet. Metab. Rep. 29, 100822. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100822 (2021).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"31622_CR21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/00004647-199811000-00004","volume":"18","author":"HE M\u00f6ller","year":"1998","unstructured":"M\u00f6ller, H. E., Weglage, J., Wiedermann, D. & Ullrich, K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J. Cereb. Blood Flow. Metab. 18, 1184\u20131191. https:\/\/doi.org\/10.1097\/00004647-199811000-00004 (1998).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"31622_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ymgme.2004.07.008","volume":"83","author":"RJ Boado","year":"2004","unstructured":"Boado, R. J., Li, J. Y., Wise, P. & Pardridge, W. M. Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport. Mol. Genet. Metab. 83, 306\u2013311. https:\/\/doi.org\/10.1016\/j.ymgme.2004.07.008 (2004).","journal-title":"Mol. Genet. Metab."},{"key":"31622_CR23","doi-asserted-by":"publisher","unstructured":"Bik-Multanowski, M. & Pietrzyk, J. J. LAT1 gene variants \u2013 potential factors influencing the clinical course of phenylketonuria. J. Inherit. Metab. Dis. 29, 684. https:\/\/doi.org\/10.1007\/s10545-006-0285-0. (2006).","DOI":"10.1007\/s10545-006-0285-0"},{"key":"31622_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bcpt.13821","volume":"133","author":"J Kahlhofer","year":"2023","unstructured":"Kahlhofer, J. & Teis, D. The human LAT1-4F2hc (SLC7A5-SLC3A2) transporter complex: physiological and pathophysiological implications. Basic. Clin. Pharmacol. Toxicol. 133, 459\u2013472. https:\/\/doi.org\/10.1111\/bcpt.13821 (2023).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"31622_CR25","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1007\/s12035-024-04506-9","volume":"62","author":"HS Ahmed","year":"2025","unstructured":"Ahmed, H. S. The multifaceted role of L-Type amino acid transporter 1 at the Blood-Brain barrier: structural implications and therapeutic potential. Mol. Neurobiol. 62, 3813\u20133832. https:\/\/doi.org\/10.1007\/s12035-024-04506-9 (2025).","journal-title":"Mol. Neurobiol."},{"key":"31622_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/s0026-0495(03)00094-5","volume":"52","author":"FG Hamel","year":"2003","unstructured":"Hamel, F. G., Upward, J. L., Siford, G. L. & Duckworth, W. C. Inhibition of proteasome activity by selected amino acids. Metabolism 52, 810\u2013814. https:\/\/doi.org\/10.1016\/s0026-0495(03)00094-5 (2003).","journal-title":"Metabolism"},{"key":"31622_CR27","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.molcel.2023.08.016","volume":"83","author":"I Livneh","year":"2023","unstructured":"Livneh, I. et al. Regulation of nucleo-cytosolic 26S proteasome translocation by aromatic amino acids via mTOR is essential for cell survival under stress. Mol. Cell. 83, 3333\u20133346e5. https:\/\/doi.org\/10.1016\/j.molcel.2023.08.016 (2023).","journal-title":"Mol. Cell."},{"key":"31622_CR28","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.ymgme.2005.07.031","volume":"86","author":"LB M\u00f8ller","year":"2005","unstructured":"M\u00f8ller, L. B. et al. Inter- individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc\/LAT1 complex. Mol. Genet. Metab. 86, S119\u2013S23. https:\/\/doi.org\/10.1016\/j.ymgme.2005.07.031 (2005).","journal-title":"Mol. Genet. Metab."},{"key":"31622_CR29","doi-asserted-by":"publisher","first-page":"100751","DOI":"10.1016\/j.ymgmr.2021.100751","volume":"27","author":"M Bik-Multanowski","year":"2021","unstructured":"Bik-Multanowski, M., Bik-Multanowska, K., Betka, I. & Madetko-Talowska, A. The rs113883650 variant of SLC7A5 (LAT1) gene May alter brain phenylalanine content in PKU. Mol. Genet. Metab. Rep. 27, 100751. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100751 (2021).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"31622_CR30","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/j.ymgmr.2020.100640","volume":"25","author":"M Bik-Multanowski","year":"2020","unstructured":"Bik-Multanowski, M. et al. Carriership of the rs113883650\/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria. Mol. Genet. Metab. Rep. 25, 100640. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100640 (2020).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"31622_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tig.2020.09.005","volume":"37","author":"HE Kamber Kaya","year":"2021","unstructured":"Kamber Kaya, H. E. & Radhakrishnan, S. K. Trash talk: mammalian proteasome regulation at the transcriptional level. Trends Genet. 37, 160\u2013173. https:\/\/doi.org\/10.1016\/j.tig.2020.09.005 (2021).","journal-title":"Trends Genet."},{"key":"31622_CR32","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1093\/hmg\/ddx327","volume":"26","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of huntington\u2019s disease and their derived neural cells. Hum. Mol. Genet. 26, 4416\u20134428. https:\/\/doi.org\/10.1093\/hmg\/ddx327 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"31622_CR33","doi-asserted-by":"publisher","first-page":"625715","DOI":"10.3389\/fcell.2021.625715","volume":"9","author":"M Kapetanou","year":"2021","unstructured":"Kapetanou, M. et al. FoxO1 is a novel regulator of 20S proteasome subunits expression and activity. Front. Cell. Dev. Biol. 9, 625715. https:\/\/doi.org\/10.3389\/fcell.2021.625715 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"31622_CR34","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"31622_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.27","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27. (2000)."},{"key":"31622_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ymgme.2015.03.006","volume":"115","author":"A Aguiar","year":"2015","unstructured":"Aguiar, A. et al. Practices in prescribing protein substitutes for PKU in europe: no uniformity of approach. Mol. Genet. Metab. 115, 17\u201322. https:\/\/doi.org\/10.1016\/j.ymgme.2015.03.006 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"31622_CR37","doi-asserted-by":"crossref","unstructured":"Ahring, K. et al. Management of phenylketonuria in European PKU centres remains heterogeneous. Mol. Genet. Metab. 141 (2024).","DOI":"10.1016\/j.ymgme.2023.108120"},{"key":"31622_CR38","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1242\/jcs.125773","volume":"126","author":"M Laplante","year":"2013","unstructured":"Laplante, M. & Sabatini, D. M. Regulation of mTORC1 and its impact on gene expression at a glance. J. Cell. Sci. 126, 1713\u20131719. https:\/\/doi.org\/10.1242\/jcs.125773 (2013).","journal-title":"J. Cell. Sci."},{"key":"31622_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/genes11090989","volume":"11","author":"CH Melick","year":"2020","unstructured":"Melick, C. H. & Jewell, J. L. Regulation of mTORC1 by upstream stimuli. Genes (Basel). 11, 989. https:\/\/doi.org\/10.3390\/genes11090989 (2020).","journal-title":"Genes (Basel)"},{"key":"31622_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar, V. et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal. Transduct. Target. Ther. 8, 375. https:\/\/doi.org\/10.1038\/s41392-023-01608-z (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"31622_CR41","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/14728222.2015.1044975","volume":"19","author":"SE Jin","year":"2015","unstructured":"Jin, S. E., Jin, H. E. & Hong, S. S. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics. Expert Opin. Ther. Targets. 19, 1319\u20131337. https:\/\/doi.org\/10.1517\/14728222.2015.1044975 (2015).","journal-title":"Expert Opin. Ther. Targets"},{"key":"31622_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11095-020-02826-8","volume":"37","author":"E Puris","year":"2020","unstructured":"Puris, E., Gynther, M., Auriola, S. & Huttunen, K. M. L-Type amino acid transporter 1 as a target for drug delivery. Pharm. Res. 37, 88. https:\/\/doi.org\/10.1007\/s11095-020-02826-8 (2020).","journal-title":"Pharm. Res."},{"key":"31622_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2013.06.013","volume":"18","author":"EP Rhee","year":"2013","unstructured":"Rhee, E. P. et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell. Metab. 18, 130\u2013143. https:\/\/doi.org\/10.1016\/j.cmet.2013.06.013 (2013).","journal-title":"Cell. Metab."},{"key":"31622_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41588-022-01270-1","volume":"55","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat. Genet. 55, 44\u201353. https:\/\/doi.org\/10.1038\/s41588-022-01270-1 (2023).","journal-title":"Nat. Genet."},{"key":"31622_CR45","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1167\/iovs.18-25497","volume":"59","author":"A Miki","year":"2018","unstructured":"Miki, A. et al. Genome-Wide association study to identify a new susceptibility locus for central serous chorioretinopathy in the Japanese population. Invest. Ophthalmol. Vis. Sci. 59, 5542\u20135547. https:\/\/doi.org\/10.1167\/iovs.18-25497 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"31622_CR46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"1000 Genomes Project Consortium","year":"2015","unstructured":"1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature 526, 68\u201374. https:\/\/doi.org\/10.1038\/nature15393 (2015).","journal-title":"Nature"},{"key":"31622_CR47","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2009.06.001","volume":"137","author":"JE Phillips","year":"2009","unstructured":"Phillips, J. E. & Corces, V. G. CTCF: master weaver of the genome. Cell 137, 1194\u20131211. https:\/\/doi.org\/10.1016\/j.cell.2009.06.001 (2009).","journal-title":"Cell"},{"key":"31622_CR48","doi-asserted-by":"publisher","unstructured":"Marina-Z\u00e1rate, E., Rodr\u00edguez-Ronchel, A., G\u00f3mez, M. J., S\u00e1nchez-Cabo, F. & Ramiro, A. R. Low-affinity CTCF binding drives transcriptional regulation whereas high-affinity binding encompasses architectural functions. iScience. 26, 106106. (2023). https:\/\/doi.org\/10.1016\/j.isci.2023.106106","DOI":"10.1016\/j.isci.2023.106106"},{"key":"31622_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ymgme.2010.10.003","volume":"102","author":"M Bik-Multanowski","year":"2011","unstructured":"Bik-Multanowski, M., Pietrzyk, J. J. & Mozrzymas, R. Routine use of CANTAB system for detection of neuropsychological deficits in patients with PKU. Mol. Genet. Metab. 102, 210\u2013213. https:\/\/doi.org\/10.1016\/j.ymgme.2010.10.003 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"31622_CR50","unstructured":"Wechsler, D. Wechsler Adult Intelligence Scale-Revised (Psychological Corporation, 1981)."},{"key":"31622_CR51","unstructured":"Grob, A. & Hagmann-von Arx, P. Intelligence and Development Scales\u20132 (IDS-2). Intelligenz- Und Entwicklungsskalen f\u00fcr Kinder Und Jugendliche [Intelligence and Development Scales for Children and adolescents] (Hogrefe, 2018)."},{"key":"31622_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jsp.2021.09.002","volume":"88","author":"A B\u00fcnger","year":"2021","unstructured":"B\u00fcnger, A., Grieder, S., Schweizer, F. & Grob, A. The comparability of intelligence test results: Group- and individual-level comparisons of seven intelligence tests. J. Sch. Psychol. 88, 101\u2013117. https:\/\/doi.org\/10.1016\/j.jsp.2021.09.002 (2021).","journal-title":"J. Sch. Psychol."},{"key":"31622_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"31622_CR54","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216\u2013W221. https:\/\/doi.org\/10.1093\/nar\/gkac194 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31622-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31622-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31622-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:03:41Z","timestamp":1766066621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31622-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["31622"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31622-w","relation":{"references":[{"id-type":"doi","id":"10.1093\/nar\/28.1.27","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43813"}}